Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
March 2013

Adjunctive L-methylfolate for Treatment-Resistant Depression
L-methylfolate may be effective and well tolerated as an adjunctive treatment for depression, but questions remain about its safety and cost.

Antidepressants and the Risk of Breast Cancer
Current data suggest that women who take antidepressants do not have an increased risk of breast cancer.

Antipsychotics and Mortality in Schizophrenia
In general, adherence to antipsychotic treatment seems to decrease the risk of mortality in patients with schizophrenia, but high doses may increase the risk, regardless of adherence.

In Brief
FDA Recommends Decreased Bedtime Dose of Zolpidem for Women; Hearing Loss Linked to Cognitive Decline

Clozapine: Monitoring for Hazards
In addition to agranulocytosis, clozapine (Clozaril and others) can cause three other potentially lethal effects: diabetic ketoacidosis, gastrointestinal hypomotility, and myocarditis.

Clozapine: Monitoring for Hazards

March 2013

For decades now, clozapine (Clozaril and others) has been the go-to medication when others have failed to sufficiently alleviate the symptoms of schizophrenia. We recently described work suggesting clozapine's efficacy in treatment-resistant cases of bipolar disorder (BTP 2013;36:7-8).1

To view the rest of this article, please: